A Phase II Trial of R115777, an Oral Farnesyltransferase Inhibitor (FTI) in Previously Untreated Patients With Advanced Urothelial Tract Transitional Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2013
At a glance
- Drugs Tipifarnib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 26 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2005 New trial record.